Research programme: macrocyclic compounds - Cyclenium Pharma/Haplogen

Drug Profile

Research programme: macrocyclic compounds - Cyclenium Pharma/Haplogen

Alternative Names: Anti-viral therapeutics - Cyclenium Pharma/Haplogen

Latest Information Update: 26 Jun 2015

Price : $50

At a glance

  • Originator Cyclenium Pharma; Haplogen
  • Class Macrocyclic compounds; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Viral infections

Most Recent Events

  • 07 May 2015 Early research in Viral infections in USA (unspecified route)
  • 07 May 2015 Cyclenium Pharma and Haplogen agree to co-develop macrocyclic compounds in Viral infections and other therapeutic indications in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top